Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D H Albert

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|July 1, 1997
Ex vivo inhibition of beta-thromboglobulin release following administration to man of ABT-299, a novel prodrug of a potent platelet activating factor antagonistD H Albert, T J Magoc, S D Menacherry, et al.
Journal of Medicinal Chemistry|December 23, 1994
N-(acyloxyalkyl)pyridinium salts as soluble prodrugs of a potent platelet activating factor antagonistS K Davidsen, J B Summers, D H Albert, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1996
Properties of ABT-299, a prodrug of A-85783, a highly potent platelet activating factor receptor antagonistD H Albert, R G Conway, T J Magoc, et al.
Advances in Prostaglandin, Thromboxane, and Leukotriene Research|January 1, 1995
ABT-299, a potent antagonist of platelet activating factorJ B Summers, D H Albert, S K Davidsen, et al.
European Journal of Pharmacology|April 23, 1997
Pharmacology of ABT-491, a highly potent platelet-activating factor receptor antagonistD H Albert, T J Magoc, P Tapang, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 22, 1998
The role of platelet-activating factor (PAF) and the efficacy of ABT-491, a highly potent and selective PAF antagonist, in experimental allergic rhinitisD H Albert, P E Malo, P Tapang, et al.
Leukemia|October 19, 2007
Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathwayJ Zhou, M Pan, Z Xie, et al.
The Pharmacogenomics Journal|February 4, 2009
Identification of genes that confer tumor cell resistance to the aurora B kinase inhibitor, AZD1152J Guo, M G Anderson, P Tapang, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitorsG S Sheppard, A S Florjancic, J R Giesler, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
The design, synthesis, and structure-activity relationships of a series of macrocyclic MMP inhibitorsD H Steinman, M L Curtin, R B Garland, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|July 1, 1997
Ex vivo inhibition of beta-thromboglobulin release following administration to man of ABT-299, a novel prodrug of a potent platelet activating factor antagonistD H Albert, T J Magoc, S D Menacherry, et al.
Journal of Medicinal Chemistry|December 23, 1994
N-(acyloxyalkyl)pyridinium salts as soluble prodrugs of a potent platelet activating factor antagonistS K Davidsen, J B Summers, D H Albert, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1996
Properties of ABT-299, a prodrug of A-85783, a highly potent platelet activating factor receptor antagonistD H Albert, R G Conway, T J Magoc, et al.
Advances in Prostaglandin, Thromboxane, and Leukotriene Research|January 1, 1995
ABT-299, a potent antagonist of platelet activating factorJ B Summers, D H Albert, S K Davidsen, et al.
European Journal of Pharmacology|April 23, 1997
Pharmacology of ABT-491, a highly potent platelet-activating factor receptor antagonistD H Albert, T J Magoc, P Tapang, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 22, 1998
The role of platelet-activating factor (PAF) and the efficacy of ABT-491, a highly potent and selective PAF antagonist, in experimental allergic rhinitisD H Albert, P E Malo, P Tapang, et al.
Leukemia|October 19, 2007
Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathwayJ Zhou, M Pan, Z Xie, et al.
The Pharmacogenomics Journal|February 4, 2009
Identification of genes that confer tumor cell resistance to the aurora B kinase inhibitor, AZD1152J Guo, M G Anderson, P Tapang, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitorsG S Sheppard, A S Florjancic, J R Giesler, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
The design, synthesis, and structure-activity relationships of a series of macrocyclic MMP inhibitorsD H Steinman, M L Curtin, R B Garland, et al.
Pageof 4